Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy

BACKGROUND: Cetuximab, an anti-EGFR monoclonal antibody, is used to treat several cancers. However, many patients who initially respond to cetuximab acquire resistance. To examine mechanisms of acquired resistance, we developed a series of cetuximab-resistant (Ctx(R)) clones derived from the cetuxim...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Mol Cancer
Glavni autori: Iida, Mari, Brand, Toni M, Starr, Megan M, Huppert, Evan J, Luthar, Neha, Bahrar, Harsh, Coan, John P, Pearson, Hannah E, Salgia, Ravi, Wheeler, Deric L
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2014
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4283113/
https://ncbi.nlm.nih.gov/pubmed/25344208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-13-242
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items